Director, US Medical Affairs, NSCLC

Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.

Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.

The Opportunity:

The Director, US Medical Affairs – Non-Small Cell Lung Cancer (NSCLC) will support the development of the US medical strategy and lead execution of assigned medical priorities across the NSCLC portfolio. The role spans first-line and subsequent-line treatment settings and includes pre-launch planning, launch readiness, post-approval medical activities, and lifecycle planning.

As a member of the US Medical Affairs Team (USMAT), the Director will translate evolving clinical evidence, external expert perspectives, and field insights into focused medical objectives and actionable plans. The individual will serve as an NSCLC scientific expert and partner across US and Global Medical Affairs, Field Medical, Clinical Development and Operations, Medical Information and Communications, HEOR/RWE, Biomarker and Companion Diagnostics, Commercial, Market Access, Patient Advocacy, Regulatory, Safety, Legal, and Compliance.

The ideal candidate brings strong lung cancer expertise, scientific rigor, and hands-on Medical Affairs experience. This individual can communicate complex evidence clearly, influence across functions, and manage multiple priorities in a fast-paced environment.

Contributes to the US NSCLC medical strategy and annual portfolio plan; lead assigned tactics with clear objectives, timelines, budgets, and measures of impact.

Conducts evidence and practice-gap assessments, incorporating US treatment patterns, stakeholder needs, competitive developments, and field insights to refine medical priorities.

Supports launch readiness, launch execution, and lifecycle planning across NSCLC assets in alignment with US and Global Medical Affairs strategies.

Leads or support scientific engagement with US external experts through advisory boards, investigator interactions, congress activities, and peer-to-peer scientific exchange.

Partners with US Field Medical on scientific priorities, insight-generation plans, training, and resources that support high-quality scientific exchange.

Synthesizes insights from external experts, field teams, advisory boards, and congresses; communicate implications and recommend actions to internal stakeholders.

Serves as an NSCLC medical content expert on cross-functional teams, providing scientifically balanced input into US strategic discussions and decisions.

Partners with HEOR/RWE, Clinical Development, and Biomarker/Companion Diagnostics teams on evidence-generation priorities, including patient identification, molecular testing, treatment sequencing, safety management, and patient outcomes.

Collaborates with Clinical Development, Clinical Operations, and Field Medical to support protocol review, site and investigator engagement, and appropriate trial awareness and enrollment activities.

Contributes to publication, congress, medical communications, and data-disclosure plans; develop or review scientific presentations, abstracts, manuscripts, educational content, and medical information response documents.

Provides medical leadership for assigned US congress activities, scientific symposia, advisory boards, and internal education, ensuring scientific accuracy and consistency.

Partner...